August 1, 2019

Sema4 Announces Location of its Second Connecticut Lab; Harbor Landing in Stamford Will Soon Be Home to 300+ Employees

 

Governor Lamont, U.S. Representative Himes, and State Senator Hwang to participate in commencement of construction ceremony taking place on August 1

Stamford, CT — August 1, 2019 — Sema4, a patient-centered health intelligence company, announced the location of the company’s second laboratory space in Connecticut for its genomic testing products and digital health services, as part of the company’s commitment to the state’s growing biotech industry. Commencement of construction for the new 70,000-square-foot facility at 62 Southfield Ave. in the Harbor Landing area of Stamford will begin on Thursday, August 1, with a ceremony that will include remarks from Governor Ned Lamont, U.S. Representative Jim Himes, and State Senator Tony Hwang.

“We are proud to make this important investment in the Stamford community to propel our continued growth in creating cutting-edge precision medicine solutions to improve the way providers deliver care for patients,” said Eric Schadt, Ph.D., Founder and Chief Executive Officer of Sema4. “Connecticut offers an optimal environment to address our company’s growing needs for qualified candidates and provides access to leading universities and medical centers.”

The lab will be designed to process more than 5,000 patient samples a day to further scale Sema4’s ability to provide important health information across several thousand diseases to patients nationwide. In addition to the laboratory, the new facility will house offices for more than 100 genetic counselors, bioinformatics specialists, and support service staff as part of the company’s comprehensive health intelligence platform services.

“As a health technology company on the leading edge of science, we are thrilled to be part of Sema4’s expansion. Their corporate mission to better understand, diagnose, and treat disease plays an important role in our community’s ability to contribute to national healthcare improvement,” said Governor Ned Lamont. “We are fortunate to have such important work and research taking place in Stamford.”

“I’m thrilled that Sema4 decided to build their newest laboratory in Stamford. By using 21st century technology to drive better health decisions, this Connecticut-based company epitomizes our region’s bright economic future. This facility will be a hub for research and development, and I look forward to Sema4’s continued success. With 300 new jobs coming to the Stamford area, Fairfield County remains an exciting place to do business,” said U.S. Representative Jim Himes.

“As the co-chair of the bioscience caucus, I deeply value the importance of genomics and precision medicine as they relate to personal healthcare,” said State Senator Tony Hwang. “Connecticut is dedicated to helping grow innovative businesses and industries in this space that will continue to drive the best clinical outcomes and deliver better diagnosis and treatment for patients.”

In addition to the new Stamford lab, in 2019, Sema4 expanded its Branford lab location and doubled the size of its headquarters in Stamford.

“Sema4’s new lab operations further our vision to position Connecticut as a hub for bioscience and tech growth,” said David Lehman, Commissioner, Connecticut Department of Economic and Community Development.

Built by CT-based builder A. Secondino & Son and designed by CT-based BL Companies, Sema4’s new laboratory will employ more than 300 people. This new facility adds to Sema4’s existing locations, including headquarters in Stamford, CT, a lab in Branford, CT, and an office in New York, NY.

 

About Sema4

Sema4 is a patient-centered health intelligence company founded on the idea that more information, deeper analysis, and increased engagement will improve the diagnosis, treatment, and prevention of disease. Sema4 is dedicated to transforming healthcare by building dynamic models of human health and defining optimal, individualized health trajectories, starting in the areas of reproductive health and oncology. Centrellis™, our innovative health intelligence platform, is enabling us to generate a more complete understanding of disease and wellness and to provide science-driven solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all.

For more information, please visit sema4.com and connect with Sema4 on Twitter, LinkedInFacebook and YouTube.


Media Contact

Victoria Steiner
415.370.5804
victoria@bioscribe.com